Regulatory approval

Published by the Health Service Executive. Approved

In combination with paclitaxel is indicated for first-line treatment of adult patients with HER2-negative metastatic breast cancer.

This is written in the approval document.

Reimbursement

Hospital

Citation

Bevacizumab 10mg/kg - 14 days, 2021, version number 6, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6942/212_V6a_Bevacizumab_10mgkg.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	HER2-negative	Invasive Breast Carcinoma	Bevacizumab, Paclitaxel

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2015-06-12	Health Service Executive	Indication approved for reimbursement.